Histogen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSTO research report →
Price Chart
About the company
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee.
- CEO
- Susan A. Knudson
- IPO
- 2013
- Employees
- 7
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on HSTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $85.44K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.02
- P/B
- 0.00
- EV/EBITDA
- 0.70
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -282.38%
- Net Margin
- -281.80%
- ROE
- -59.67%
- ROIC
- -58.85%
Latest fiscal year · YoY change
- Revenue
- $3.77M+310.1%
- Gross Profit
- $3.77M+439.2%
- Op Income
- $-10,643,000
- Net Income
- $-10,621,000+29.0%
- EPS
- $-3.46+53.9%
- OCF Growth
- +33.4%
- FCF Growth
- +33.0%
- 52W High
- $0.02
- 52W Low
- $0.02
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.12
- RSI (14)
- 68
- Avg Volume
- 0
No earnings-call transcripts are available for HSTO yet.
- Free Float
- 97.1%
- Shares Outstanding
- 4.27M
- Float Shares
- 4.15M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 23 | Windham-Bannister Susan Richards | other | 6,835 |
| Jun 20, 23 | Satz Brian | other | 6,835 |
| Jun 20, 23 | KISNER DANIEL L | other | 6,835 |
| Jun 20, 23 | Jackson Jonathan | other | 6,835 |
| Jun 20, 23 | Fuhrmann Rochelle | other | 6,835 |
| Jun 20, 23 | Crean David Hugh | other | 6,835 |
| Mar 10, 23 | Reyes Joyce | other | 47,417 |
| Mar 10, 23 | Reyes Joyce | other | 16,659 |
| Mar 10, 23 | Reyes Joyce | sell | 4,452 |
| Mar 10, 23 | Reyes Joyce | sell | 7,833 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HSTO coverage
Recent articles, reports, and earnings notes.
No research on HSTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HSTO report →Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
globenewswire.com · Apr 18
Histogen Announces Second Adjournment of Special Meeting of Stockholders
globenewswire.com · Dec 14
Histogen Announces Adjournment of Special Meeting of Stockholders
globenewswire.com · Dec 5
Histogen Announces Board Approval of Complete Liquidation and Dissolution
globenewswire.com · Sep 18
Top Sectors to Explore for Penny Stocks to Buy
pennystocks.com · Mar 20
Penny Stock Psychology: Developing a Winning Mindset
pennystocks.com · Mar 18
Why Is Histogen (HSTO) Stock Up 37% Today?
investorplace.com · Mar 17
Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
businesswire.com · Jan 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.